- Trials with a EudraCT protocol (21)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
21 result(s) found for: Resistance training.
Displaying page 1 of 2.
EudraCT Number: 2014-000047-33 | Sponsor Protocol Number: VitD-EX1.0 | Start Date*: 2014-03-20 |
Sponsor Name:VU University Medical Centre | ||
Full Title: The effect of high-resistance muscle strength training and vitamin D supplementation in persons with knee osteoarthritis | ||
Medical condition: knee osteoarthritis vitamin D deficiency | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-004872-47 | Sponsor Protocol Number: NSAID2015 | Start Date*: 2015-07-20 |
Sponsor Name:Karolinska Institutet, Department of Laboratory Medicine, Clinical Physiology C1:82,Karolinska Univ. Hosp., Huddinge | ||
Full Title: The effects of COX-inhibiting drugs on skeletal muscle adaptations to resistance exercise in healthy adults. | ||
Medical condition: Human skeletal muscle adaptations to resistance exercise (non-disease related). | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-000563-41 | Sponsor Protocol Number: IMIMFTCL/GH/4 | Start Date*: 2014-08-08 |
Sponsor Name:Consorci Mar Parc de Salut de Barcelona (Parc de Salut Mar) | ||
Full Title: Recombinant hGH Biomarkers Discovery | ||
Medical condition: Healthy volunteers. There is not intended indication. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2009-011448-20 | Sponsor Protocol Number: 2008.11.007 | Start Date*: 2009-06-22 | |||||||||||
Sponsor Name:Dutch Diabetes Research Foundation | |||||||||||||
Full Title: Hyperoxic exercise training as an innovative therapy to improve metabolic control, endothelial dysfunction and physical fitness in deconditioned type 2 diabetes patients | |||||||||||||
Medical condition: insulin resistance, endothelial dysfunction, cardiovascular fitness, lipid metabolism and glycemic control in deconditioned non-insulin dependent type 2 diabetes patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002959-34 | Sponsor Protocol Number: RETRAP | Start Date*: 2013-03-11 | |||||||||||
Sponsor Name:Sønderjylland Hospital, department of neurology | |||||||||||||
Full Title: RETRAP - A double blind, randomized, placebo controlled study of the effect of the combination of resistance training and prolonged release fampridine on muscle strength in the lower extremities, w... | |||||||||||||
Medical condition: Multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002131-34 | Sponsor Protocol Number: GS-US-357-1394 | Start Date*: 2015-05-07 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 2, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Study of GS-4997 in Subjects with Pulmonary Arterial Hypertension | |||||||||||||
Medical condition: Men and women, ages 18 through 75 years, with a diagnosis of idiopathic PAH, heritable PAH or PAH associated with connective tissue disease (PAH-CTD), congenital heart defects (repaired), drug and ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) NL (Completed) ES (Completed) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004971-42 | Sponsor Protocol Number: RVT-1201-2002 | Start Date*: 2021-10-26 | |||||||||||
Sponsor Name:Altavant Sciences GmbH | |||||||||||||
Full Title: A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Rodatristat Ethyl in Patients with Pulmonary Arterial Hypertension | |||||||||||||
Medical condition: Pulmonary Arterial Hypertension (PAH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) LV (Prematurely Ended) FR (Completed) BE (Completed) CZ (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended) BG (Prematurely Ended) ES (Ongoing) AT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-012621-12 | Sponsor Protocol Number: R&D2008GR03 | Start Date*: 2009-08-06 | |||||||||||
Sponsor Name:University of Dundee | |||||||||||||
Full Title: Maximising physical function in later life: a 2 centre randomised trial of progressive resistance exercise training in combination with ACE inhibition | |||||||||||||
Medical condition: Age related decline in muscle function (sarcopenia) | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005322-68 | Sponsor Protocol Number: farm 69j aj9 | Start Date*: 2007-10-30 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI | |||||||||||||
Full Title: Low-dose oral imatinib in the treatment of scleroderma pulmonary involvement: a phase II pilot study | |||||||||||||
Medical condition: Systemic Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001656-18 | Sponsor Protocol Number: INOCOV-19 | Start Date*: 2020-05-19 |
Sponsor Name:Oslo University Hospital | ||
Full Title: Inhaled Nitric Oxide As A Bridge To Mechanical Ventilation In Patients With Suspected Covid-19 Respiratory Failure | ||
Medical condition: Severe respiratory failure in patients with confirmed, suspected or probable Covid- 19 disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2007-003328-39 | Sponsor Protocol Number: NS-304/-02 | Start Date*: 2008-04-25 | ||||||||||||||||||||||||||
Sponsor Name:Actelion Pharmaceuticals Ltd | ||||||||||||||||||||||||||||
Full Title: A multi-centre, multinational, open-label single-dose acute hemodynamic study followed by a multi-centre, multinational, randomized, double-blind, parallel-group, placebo controlled study to assess... | ||||||||||||||||||||||||||||
Medical condition: pulmonary arterial hypertension (PAH) (idiopathic PAH, familial PAH, and PAH associated with collagen disease, corrected congenital vitium or anorexigen use) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: BE (Completed) FR (Completed) DE (Completed) HU (Completed) AT (Completed) GB (Completed) IT (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-001910-13 | Sponsor Protocol Number: AV-101-002 | Start Date*: 2022-02-21 | ||||||||||||||||||||||||||
Sponsor Name:Aerovate Therapeutics, Inc. | ||||||||||||||||||||||||||||
Full Title: IMPAHCT: A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 24-Week Dose Ranging and Confirmatory Study to Evaluate the Safety and Efficacy of AV-101 in Patients with Pulmonary Arterial Hy... | ||||||||||||||||||||||||||||
Medical condition: Pulmonary Arterial Hypertension (PAH) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: FR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) CZ (Trial now transitioned) GR (Trial now transitioned) PT (Trial now transitioned) IE (Trial now transitioned) AT (Trial now transitioned) LV (Trial now transitioned) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004887-74 | Sponsor Protocol Number: AC-065D301 | Start Date*: 2019-08-14 | |||||||||||
Sponsor Name:Actelion Pharmaceuticals Ltd | |||||||||||||
Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Study in Participants with Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag. | |||||||||||||
Medical condition: sarcoidosis-associated pulmonary hypertension (SAPH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) DE (Completed) HU (Prematurely Ended) PL (Completed) ES (Ongoing) BE (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000438-79 | Sponsor Protocol Number: CCD-05993AA1-16 | Start Date*: 2017-09-11 | |||||||||||
Sponsor Name:Chiesi Farmaceutici S.p.A. | |||||||||||||
Full Title: Open label, prospective, exploratory study to investigate the effect of inhaled CHF5993 pMDI on central and peripheral airway dimensions in COPD patients by Functional Respiratory Imaging | |||||||||||||
Medical condition: COPD | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002370-30 | Sponsor Protocol Number: CCD-1205-PR-0087 | Start Date*: 2012-10-11 | |||||||||||
Sponsor Name:Chiesi Farmaceutici S.p.A. | |||||||||||||
Full Title: A PHASE II, MONOCENTRE, OPEN, RANDOMIZED, 6-WAY CROSS-OVER CLINICAL PHARMACOLOGY STUDY TO EVALUATE THE LUNG BIOAVAILABILITY OF BDP/B17MP AND FORMOTEROL AND THE TOTAL SYSTEMIC EXPOSURE ACROSS TWO D... | |||||||||||||
Medical condition: asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003587-36 | Sponsor Protocol Number: 684/MODREC/15 | Start Date*: 2016-04-13 | ||||||||||||||||
Sponsor Name:Directorate of Defence Rehabilitation | ||||||||||||||||||
Full Title: Chronic Tendinopathy: The Biomechanical Associations and EfFicacy of Injectable Therapy (BE FIT) Study | ||||||||||||||||||
Medical condition: Chronic degenerative Achilles and patella tendinopathy patients, with neovascularisation on USS, who have failed best practice rehabilitation including Eccentric Loading (EL), Heavy Slow Resistance... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002556-32 | Sponsor Protocol Number: ANTIC:6672 | Start Date*: 2013-09-05 | |||||||||||
Sponsor Name:The Newcastle upon Tyne Hospitals NHS Foundation Trust | |||||||||||||
Full Title: Antibiotic treatment for intermittent bladder catheterisation: A randomised controlled trial of once daily prophylaxis (The AnTIC study) | |||||||||||||
Medical condition: Recurrent urinary tract infection in people who use intermittent bladder catheterisation. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002453-28 | Sponsor Protocol Number: GR-2018-12368292 | Start Date*: 2021-08-23 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA ARCISPEDALE SANTA MARIA NUOVA/IRCCS DI REGGIO EMILIA | |||||||||||||
Full Title: First line Immunotherapy-chemotherapy versus Immunotherapy-chemotherapy Combined With Stereotactic Body Radiation for Metastatic NSCLC patients: A Phase II Randomized, Open Label Clinical Trial. | |||||||||||||
Medical condition: Patients with both squamous and nonsquamous metastatic non-small cell lung cancer (NSCLC) wild type in EGFR, KRAS, ALK and ROS1. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-004546-15 | Sponsor Protocol Number: 12-PP-12 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:CHU de Nice | |||||||||||||
Full Title: Assessment of incidence of adverse events in a naive pediatric population treated with an antipsychotic drug over 12 months follow-up | |||||||||||||
Medical condition: severe behavioral disorders in mental retardation, autistic syndromes schizophrenia psychosis | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004010-10 | Sponsor Protocol Number: UoL001253 | Start Date*: 2017-10-20 | |||||||||||
Sponsor Name:University of Liverpool | |||||||||||||
Full Title: PETReA: Phase 3 evaluation of PET-guided, Response-Adapted therapy in patients with previously untreated, high tumour burden follicular lymphoma | |||||||||||||
Medical condition: Previously untreated, high tumour burden follicular lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
